Zepbound Shows Superior Weight Loss Results Over Wegovy in Head-to-Head Trial, Study Finds
Zepbound injection pens in packaging
In a clinical trial sponsored by Eli Lilly, Zepbound demonstrated superior weight loss results compared to Wegovy. The SURMOUNT-5 Phase 3b trial revealed that participants using tirzepatide (Zepbound) lost an average of 20.2% of their body weight, while those using semaglutide (Wegovy) lost 13.7%.
Key findings from the 72-week trial:
- Tirzepatide users lost an average of 50.3 pounds
- Semaglutide users lost an average of 33.1 pounds
- 32% of tirzepatide users achieved ≥25% body weight reduction
- Participants showed greater reductions in waist circumference and improved cardiometabolic risk factors
The superior performance of tirzepatide is attributed to its dual-action mechanism, targeting both GLP-1 and GIP receptors, while semaglutide only targets GLP-1 receptors. This dual approach provides enhanced appetite control and improved energy metabolism.
Side Effects:
- Both medications showed similar safety profiles
- Most common: mild to moderate gastrointestinal issues
- Semaglutide: higher treatment discontinuation rate
- Tirzepatide: more injection-site reactions, generally mild
Treatment Considerations:
- Both medications are effective for weight loss
- No need to switch if currently successful on Wegovy
- Best results achieved when combined with lifestyle changes
- Insurance coverage remains a significant barrier to access
- Cost may limit availability for many patients
While tirzepatide shows promise as a leading obesity treatment, success still requires a comprehensive approach including diet, exercise, and lifestyle modifications. The medication's effectiveness must be weighed against insurance coverage and cost considerations when determining the most appropriate treatment option for each patient.